Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with or without LY2157299 in mCRPC
NCT02452008Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2016
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of galunisertib in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started May 2016; status: active, not recruiting.
02
Drugs
galunisertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02452008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452008.